Best way to switch osteoporosis meds after denosumab? small study tests timing
NCT ID NCT04177940
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 45 people with osteoporosis caused by long-term steroid use. Participants had stopped taking denosumab and were switched to either zoledronic acid or alendronate at different times. The goal was to see which timing and drug best controlled bone loss markers. Results may guide future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
denosumab, zoledronic acid, alendronate
What this could lead to
If successful, this could help doctors choose the best follow-up treatment to prevent bone loss after stopping denosumab in people on long-term steroids.
What could go wrong
This is a small pilot study with only 45 participants, so results may not apply to everyone. The study measures bone turnover markers, not actual fractures, so real-world benefits are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States